Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No.

IF 5.4 3区材料科学 Q2 CHEMISTRY, PHYSICAL

ACS Applied Energy Materials Pub Date : 2024-08-17 DOI:10.1016/j.euf.2024.07.015

Fred Saad

引用次数: 0

Abstract

Patients who benefit the most from combinations of an androgen receptor pathway inhibitor and a PARP inhibitor are those with a BRCA mutation, but there are certainly patients without BRCA mutations who will benefit from this treatment strategy.

查看原文本刊更多论文

只有 BRCA 基因突变的患者才应该接受雄激素受体通路抑制剂和 PARP 抑制剂联合治疗转移性阉割耐药前列腺癌吗？答案是否定的。

从雄激素受体通路抑制剂和 PARP 抑制剂联合治疗中获益最多的患者是那些 BRCA 基因突变的患者，但当然也有一些没有 BRCA 基因突变的患者会从这种治疗策略中获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Energy Materials Materials Science-Materials Chemistry

CiteScore

10.30

自引率

6.20%

发文量

1368

期刊介绍： ACS Applied Energy Materials is an interdisciplinary journal publishing original research covering all aspects of materials, engineering, chemistry, physics and biology relevant to energy conversion and storage. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important energy applications.